COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience
Clinical and Translational Neuroscience
; 6(1):6, 2022.
Article
in English
| MDPI | ID: covidwho-1702322
ABSTRACT
The COVID-19 pandemic specifically affects the management and treatment of patients with autoimmune neurological disorders. Major concerns include potentially higher risks of infection or severe disease course under certain immunotherapies used to treat those disorders and the influence of COVID-19 on the underlying disease. We present data of the neuroimmunological outpatient department of the University Hospital of Bern (Switzerland). 24 cases were analyzed, 19 of them suffered from Multiple Sclerosis. Of these 24 patients, 6 were hospitalized, 2/6 were treated in the Intensive Care Unit. Possible risk factors for severe course (defined as need for hospitalization) observed in our cohort included cardiovascular risk factors, treatment with B-cell depleting agents, Sphingosine-1 Phosphate Receptor Modulators, and oral steroid therapies. These data are based on a small, retrospective observational cohort and should be interpreted with caution, although they are in line with several other cohort studies.
Full text:
Available
Collection:
Databases of international organizations
Database:
MDPI
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Language:
English
Journal:
Clinical and Translational Neuroscience
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS